These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9108849)

  • 1. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.
    Kelly KM; Butler RB; Farace L; Cohen AR; Manno CS
    J Pediatr; 1997 Apr; 130(4):537-40. PubMed ID: 9108849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.
    White GC; Courter S; Bray GL; Lee M; Gomperts ED
    Thromb Haemost; 1997 Apr; 77(4):660-7. PubMed ID: 9134639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
    Iorio A; Halimeh S; Holzhauer S; Goldenberg N; Marchesini E; Marcucci M; Young G; Bidlingmaier C; Brandao LR; Ettingshausen CE; Gringeri A; Kenet G; Knöfler R; Kreuz W; Kurnik K; Manner D; Santagostino E; Mannucci PM; Nowak-Göttl U
    J Thromb Haemost; 2010 Jun; 8(6):1256-65. PubMed ID: 20345722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The uptake of recombinant Factor VIII in the Netherlands.
    Zwart-van Rijkom JE; Plug I; Rosendaal FR; Leufkens HG; Broekmans AW;
    Br J Haematol; 2002 Nov; 119(2):332-41. PubMed ID: 12406065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
    Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
    Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Arkin S; Rose E; Forster A; Aledort LM
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):47-51. PubMed ID: 1908129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low recovery in vivo of highly purified factor VIII in patients with hemophilia.
    Manno CS; Butler RB; Cohen AR
    J Pediatr; 1992 Nov; 121(5 Pt 1):814-8. PubMed ID: 1432437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
    Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
    PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system.
    Esmon PC; Kuo HS; Fournel MA
    Blood; 1990 Oct; 76(8):1593-600. PubMed ID: 1698481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.